Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02286440 · ClinicalTrials.gov registry record · NA
A PK/PD Genetic Variation Treatment Algorithm Versus Treatment As Usual for Adolescent Management Of Depression
A NA study of Depression, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 179
- Enrollment target
- 2
- Study locations
NCT02286440: Completed NA study of Depression, sponsored by Mayo Clinic.
NCT02286440 is a NA study of Depression that has completed, run by Mayo Clinic. The registered enrollment target is 179 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02286440, a NA study of Depression, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 179 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overall goal of this investigator-initiated trial is to evaluate the impact of platform algorithm products designed to rapidly identify pharmacokinetic (PK) and/or pharmacodynamic (PD) genomic variation on treatment outcome of depression in adolescents. This new technology may have the potential to optimize treatment selection by improving response, minimizing unfavorable adverse events / side effects and increasing treatment adherence
Primary Outcome
The primary outcome measure is the baseline to endpoint change in the Children's Depression Rating Scale, Revised (CDRS-R).
Conditions Studied
Interventions
- OTHER Treatment as usual
- OTHER AssureRx GeneSight genotyping results
Study Locations (2)
Minnesota
- Mayo Clinic in Rochester - Rochester
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2015-02 |
| Est. Completion | 2019-02-06 |
| Phase | NA |
What the finished NCT02286440 record still lists
NCT02286440 is an interventional study that assigns participants to a tested intervention. The registered 179 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Treatment as usual is the first listed.
NCT02286440 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02286440 about?
NCT02286440 is a clinical study titled "A PK/PD Genetic Variation Treatment Algorithm Versus Treatment As Usual for Adolescent Management Of Depression". The overall goal of this investigator-initiated trial is to evaluate the impact of platform algorithm products designed to rapidly identify pharmacokinetic (PK) and/or pharmacodynamic (PD) genomic variation on treatment outcome of depression in adolescents. This new technology may have the potential...
What is the current status of trial NCT02286440?
This trial is currently completed. It is a NA study. The enrollment target is 179 participants. The study started on 2015-02. Estimated completion is 2019-02-06.
What conditions does trial NCT02286440 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT02286440?
The interventions under investigation include: Treatment as usual (OTHER), AssureRx GeneSight genotyping results (OTHER).
Who is sponsoring clinical trial NCT02286440?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02286440 being conducted?
This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02286440's enrollment target sits among peer trials
179 229th of 679 higher than 451 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06581198 · 179 participants · Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
- NCT07356323 · 179 participants · NA
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia